Elicio Therapeutics, Inc. (ELTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of ELTX. The 7-day demo opens the 1M and 3M ranges and puts ELTX on your watchlist.
Start 7-day demoLatest ELTX insider trades
About Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- BOSTON, MA
- 33
- 2023
- XNAS
ELTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 11 | 517,502 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ELTX insider transactions (Form 4)
3630 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Julian Adams - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Carol Gail Ashe - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Yekaterina Chudnovsky - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Allen Nissenson - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
 Robert R. Ruffolo - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Karen J. Wilson - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Jay Venkatesan - Director | Grant or award | Stock Option (Right to Buy) | 21,750 | $0.00 | - | |
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 64,643 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 52,832 | $0.00 | - | |
| Preetam Shah - Officer | Grant or award | Stock Option (Right to Buy) | 60,833 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 186,944 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Common Stock | 73,600 footnote F1 | $0.00 footnote F1 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 147,200 | $0.00 | - | |
| ||||||
| Preetam Shah - Officer | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 footnote F1 | - | |
| Preetam Shah - Officer | Grant or award | Stock Option (Right to Buy) | 47,900 | $0.00 | - | |
| ||||||
| Peter Demuth - Officer | Grant or award | Common Stock | 20,800 footnote F1 | $0.00 footnote F1 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 41,600 | $0.00 | - | |
| ||||||
| Christopher Haqq - Officer | Grant or award | Common Stock | 25,400 footnote F1 | $0.00 footnote F1 | - | |
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 50,900 | $0.00 | - | |
| ||||||
| Karen J. Wilson - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Julian Adams - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Robert R. Ruffolo - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Peter Demuth - Officer | Option exercise | Common Stock | 381 | $4.41 | $2K | |
| Peter Demuth - Officer | Option exercise | Stock Option (Right to Buy) | 381 | $0.00 | - | |
| Jay Venkatesan - Director | Other | Common Stock | 50,000 | $0.01 | $500 | |
| Jay Venkatesan - Director | Other | Warrant to Purchase Common Stock | 50,000 | $0.00 | - | |
| Carol Gail Ashe - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Yekaterina Chudnovsky - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Allen Nissenson - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Jay Venkatesan - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Karen J. Wilson - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Julian Adams - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Robert R. Ruffolo - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 91,600 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 29,800 | $0.00 | - | |
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 28,200 | $0.00 | - | |
ELTX insider trading FAQ
What is the latest insider trade for ELTX?
Elicio Therapeutics, Inc. (ELTX) had 11 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for ELTX runs to 30 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ELTX stock?
No insider purchases of ELTX were filed in the last 90 days.
How many insiders are selling ELTX stock?
No insider sales of ELTX were filed in the last 90 days.
Where can I see ELTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ELTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Julian Adams view on EDGAR
- - Carol Gail Ashe view on EDGAR
- - Yekaterina Chudnovsky view on EDGAR
- - Allen Nissenson view on EDGAR
- - Robert R. Ruffolo view on EDGAR
- - Karen J. Wilson view on EDGAR
- - Jay Venkatesan view on EDGAR
- - Christopher Haqq view on EDGAR
- - Peter Demuth view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ELTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ELTX with a 7-day demo
- ELTX on your watchlist
- Every ELTX Form 4 filing on record
- Up to 3 months of ELTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
